HLA配型与PTCy:对CIBMTR数据集采用倾向性评分匹配和供者年龄的再分析
该研究对CIBMTR数据集中接受统一PTCy方案预防GVHD的患者进行再分析,采用倾向性评分按1:5匹配MUD与Haplo移植并加入供者年龄变量。匹配后两组基线特征无显著差异,总体生存、无病生存、复发及非复发死亡率均无显著差异;降低强度预处理队列中MUD组非复发死亡率风险更低。作者认为PTCy背景下HLA全合的意义可能不如既往报道,及时找到年轻且至少半相合供者可能更重要。
要点
- 倾向性评分1:5匹配MUD与Haplo移植后,两组所有测量基线特征无显著差异。
- 匹配后总体生存、无病生存、复发率及非复发死亡率在MUD与Haplo组间均无显著差异。
- 降低强度预处理队列中MUD组非复发死亡率风险低于Haplo组,其他临床结局无显著差异。
核心结论
- 作者认为,PTCy方案下HLA全合对移植结局的影响可能不如既往报道的那样有意义。
- 作者提出,若能及时找到年轻且至少半相合(相关或无关)供者,可能比寻找全合供者更重要,尤其当后者导致移植延迟或使用年长供者时。
研究设计与样本
- 本研究为对CIBMTR数据集的再分析,采用倾向性评分匹配并额外加入供者年龄变量。
- 将MUD移植按1:5比例与Haplo移植进行匹配。
主要发现
- 匹配后两组所有测量基线特征均无显著差异。
- 总体生存:MUD vs Haplo死亡HR为0.95(95%CI 0.65-1.16),P=0.75。
- 无病生存:MUD vs Haplo复发或死亡HR为0.98(95%CI 0.73-1.18),P=0.89。
- 复发率:MUD vs Haplo HR为1.06(95%CI 0.77-1.38),P=0.69;非复发死亡率:MUD vs Haplo HR为0.85(95%CI 0.42-1.13),P=0.49。
- 按预处理强度分层后,降低强度预处理队列中MUD组非复发死亡率风险低于Haplo组,HR为0.56(95%CI 0.14-0.99),P=0.05,其他临床结局无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blood or marrow transplantation (BMT) outcomes using haploidentical donors (Haplo) and posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis compare favorably to HLA-matched donors using calcineurin inhibitor-based prophylaxis. A recent Center for International Blood and Marrow Transplant Research analysis of patients receiving homogenous PTCy-based prophylaxis found that, with reduced intensity conditioning, Haplo BMTs had worse outcomes than matched unrelated donor (MUD) BMTs. Due to significant differences between groups, we reanalyzed the dataset using propensity score matching and, additionally, added a donor age variable. After matching MUD BMTs to Haplo BMTs in a 1:5 ratio, no significant differences were found between groups across all measured baseline characteristics. Outcomes analyses demonstrated no significant differences in overall survival (hazard ratio [HR] of mortality with MUD vs Haplo [95% confidence interval], 0.95 [0.65-1.16], P = .75), disease-free survival (HR of relapse or death, 0.98 [0.73-1.18], P = .89), relapse rate (HR, 1.06 [0.77-1.38], P = .69), or nonrelapse mortality (NRM) (HR, 0.85 [0.42-1.13], P = .49) between groups. After stratification by conditioning intensity, MUD BMTs in the reduced-intensity cohort had lower risk of NRM (HR, 0.56 [0.14-0.99], P = .05), with no significant difference in other clinical outcomes. These results suggest the effect of HLA matching on BMT outcomes with PTCy is less meaningful than previously reported. Timely identification of a young, at least half-matched (related or unrelated) donor may be more important than finding a fully matched donor if the latter leads to a delay in BMT or use of an older donor.
引用
- Ambinder A, Jain T, Tsai HL, et al. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022. PMID: 35613462. doi:10.1182/bloodadvances.2022007741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。